A classification tree approach for improving the utilization of flow cytometry testing of blood specimens for B-cell non-Hodgkin lymphoproliferative disorders

References

• Montserrat E, Moreno C. Chronic lymphocytic leukaemia: a short overview. Ann Oncol 2008;19(Suppl. 7):vii320–vii325.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ. Just exactly how common is CLL? Leuk Res 2009; 33:1452–1453.
   PubMed Web of Science ®Google Scholar
• Seftel MD, Demers AA, Banerji V, et al. High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: a population-based Canadian cohort. Leuk Res 2009;33:1463–1468.
   PubMed Web of Science ®Google Scholar
• Stewart DA, Chen C, Sehn LH, et al. A Canadian perspective on the management of chronic lymphocytic leukemia. In: New Evidence in Oncology, March 2010. Available from: http://newevidence.com/oncology/papers/pdf/paper-201003.pdf
   Google Scholar
• Swerdlow S, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. France: IARC Press; 2008.
   Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Dagklis A, Fazi C, Scarfo L, et al. Monoclonal B lymphocytosis in the general population. Leuk Lymphoma 2009;50:490–492.
   PubMed Web of Science ®Google Scholar
• Nieto WG, Teodosio C, Lopez A, et al. Non-CLL-like monoclonal B-cell lymphocytosis in the general population: prevalence and phenotypic/genetic characteristics. Cytometry B Clin Cytom 2010; 78(Suppl. 1):S24–S34.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Kay NE, Jenkins G, et al. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 2009;113:4188–4196.
   PubMed Web of Science ®Google Scholar
• Breiman L, Friedman J, Stone CJ, et al. Classification and regression trees. Boca Raton, FL: CRC Press; 1984.
   Google Scholar
• Hill OT, Mason TJ, Schwartz SW, et al. Improving prostate cancer detection in veterans through the development of a clinical decision rule for prostate biopsy. BMC Urol 2013;13:6.
   PubMed Web of Science ®Google Scholar
• Su Y, Shen J, Qian H, et al. Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer Sci 2007;98:37–43.
   PubMed Web of Science ®Google Scholar
• Nguyen CT, Fu AZ, Gilligan TD, et al. Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis. J Clin Oncol 2010;28:119–125.
   PubMed Web of Science ®Google Scholar
• Barnholtz-Sloan JS, Guan X, Zeigler-Johnson C, et al. Decision tree-based modeling of androgen pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2011;20:1146–1155.
   PubMed Web of Science ®Google Scholar
• Taghipour Zahir S, Binesh F, Mirouliaei M, et al. Malignancy risk assessment in patients with thyroid nodules using classification and regression trees. J Thyroid Res 2013;2013:983953.
   PubMedGoogle Scholar
• Afonso AM, Ebell MH, Gonzales R, et al. The use of classification and regression trees to predict the likelihood of seasonal influenza. Fam Pract 2012;29:671–677.
   PubMed Web of Science ®Google Scholar
• Kajungu DK, Selemani M, Masanja I, et al. Using classification tree modelling to investigate drug prescription practices at health facilities in rural Tanzania. Malar J 2012;11:311.
   PubMed Web of Science ®Google Scholar
• Spira S. The cost of using flow cytometry to evaluate bone marrow. Am J Clin Pathol 1999;111:710.
   PubMed Web of Science ®Google Scholar
• Shapiro HM. Thecytometric future: it ain't necessarily flow! Methods Mol Biol 2011;699:471–482.
   Google Scholar
• Moore J, Roederer M. The flow cytometry shared resource laboratory: best practices to assure a high-quality, cost-effective partnership with biomedical research laboratories. Cytometry A 2009; 75:643–649.
   PubMed Web of Science ®Google Scholar
• Malacrida A, Perseghin P. Indications for a cost-saving policy in routine flow cytometry. Transfus Sci 1998;19:45–51.
   PubMedGoogle Scholar
• Hanson C, Plumhoff E. Test utilization and the clinical laboratory. Can J Pathol Winter 2012;113–117.
   Google Scholar
• Barnett R, Shustack A. Cost containment: the Americas. Canada. New Horizons 1994;2:332–335.
   PubMedGoogle Scholar
• Woolhandler S, Campbell T, Himmelstein DU. Costs of health care administration in the United States and Canada. N Engl J Med 2003; 349:768–775.
   PubMed Web of Science ®Google Scholar
• Himmelstein DU, Woolhandler S. Cost control in a parallel universe: medicare spending in the United States and Canada. Arch Intern Med 2012;172:1764–1766.
   PubMed Web of Science ®Google Scholar
• Naugler C. A perspective on laboratory utilization management from Canada. Clin Chim Acta 2014;427:142–144.
   PubMed Web of Science ®Google Scholar
• Janossy G. The changing pattern of “smart” flow cytometry (S-FC) to assist the cost-effective diagnosis of HIV, tuberculosis, and leukemias in resource-restricted conditions. Biotechnol J 2008;3:32–42.
   PubMed Web of Science ®Google Scholar
• Buranapraditkun S, Nookhai S, Ubolyam S, et al. Cost savings by reagent reduction in flow cytometry-based CD4 + T cell counts: an approach to improve accessibility for HIV management. Asian Pac J Allergy Immunol 2007;25:83–89.
   PubMed Web of Science ®Google Scholar
• Marsee DK, Li B, Dorfman DM. Single tube, six-color flow cytometric analysis is a sensitive and cost-effective technique for assaying clonal plasma cells. Am J Clin Pathol 2010;133:694–699.
   PubMed Web of Science ®Google Scholar
• Bulian P, Del Poeta G, Gattei V. How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemia. Hematol Oncol 2009;27:186–189.
   PubMed Web of Science ®Google Scholar
• Gentile TC, Uner A, Hutchison R, et al. CD3+, CD56 + aggressive variant of large granular lymphocyte leukemia. Blood 1994;84: 2315–2321.
   PubMed Web of Science ®Google Scholar